Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc ...

Canaccord analyst Kingsley Crane raised the firm’s price target on CrowdStrike (CRWD) to $420 from $370 and keeps a Buy rating on the shares.

Canaccord raised the firm’s price target on Okta (OKTA) to $100 from $94 and keeps a Hold rating on the shares. The firm said they reported ...

TTEC (NASDAQ:TTEC – Free Report) had its target price reduced by Canaccord Genuity Group from $4.50 to $3.50 in a research ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...

Clover Health Investments (NASDAQ:CLOV – Free Report) had its target price raised by Canaccord Genuity Group from $4.20 to $4.50 in a research report report published on Monday morning,Benzinga ...

Find insight on Fresnillo, the copper market, Australian mining, and more in the latest Market Talks covering Basic Materials ...

Revenue for Q4 2024 reached $100.9 million, up 38% year-over-year, driven by a 17% increase in MTMs and an 18% rise in ARPU. Adjusted EBITDA for the quarter was $33.4 million, marking a 35% sequential ...

Okta Inc (NASDAQ:OKTA) shares are trading higher Tuesday on the heels of the company's better-than-expected financial results. Multiple analysts also upgraded the stock and raised price targets ...

Fintel reports that on February 28, 2025, Canaccord Genuity downgraded their outlook for ICF International (NasdaqGS:ICFI) ...

Analysts at Canaccord Genuity reiterated their 135.0p target price on airside solutions developer Aurrigo International on ...

NuScale Power Corporation (NYSE: SMR) Q4 2024 Earnings Call Transcript March 3, 2025 NuScale Power Corporation beats earnings expectations. Reported EPS is $0.6, expectations were $-0.11.